Coherus Oncology Competitors and Similar CompaniesClear all

Coherus Oncology's competitors and similar companies include Genentech, AstraZeneca, Pfizer and Regeneron Pharmaceuticals.

	Coherus Oncology Coherus BioSciences is a biopharmaceutical company that focuses on the research, development, and commercialization of cancer treatments.	Genentech Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines.	AstraZeneca AstraZeneca is a biopharmaceutical company specializing in the discovery, development, manufacturing, and marketing of prescription medicines.	Pfizer Pfizer is a research-based biopharmaceutical company engaged in the discovery, development, manufacture, and distribution of healthcare products.	Regeneron Pharmaceuticals Regeneron Pharmaceuticals is a biopharmaceutical company that develops, manufactures, and markets medicines.
Founding Date	Founding Date 2010	Founding Date 1976	Founding Date 1999	Founding Date 1849	Founding Date 1988
Type	Type Public	Type Subsidiary	Type Public	Type Public	Type Public
Tags	Tags Healthcare biotech oncology therapy	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech clinical research drug development oncology pharma	Tags Healthcare biotech clinical research drug development pharma	Tags Healthcare biotech clinical research drug development pharma
Locations	Locations Redwood City, US HQ Camarillo, US	Locations South San Francisco, US HQ Hillsboro, US Oceanside, US Portland, US South San Francisco, US South San Francisco, US South San Francisco, US see more	Locations Cambridge, GB HQ Alger, DZ Buenos Aires, AR Macquarie Park, AU Macquarie Park, AU North Ryde, AU Wien, AT see more	Locations New York, US HQ Buenos Aires, AR Villa Adelina, AR Footscray, AU Mulgrave, AU Sydney, AU Wien, AT see more	Locations Tarrytown, US HQ Mississauga, CA Courbevoie, FR München, DE Bengaluru, IN Dublin, IE Limerick, IE see more
Employees	Employees 14736% decrease	Employees 18,077	Employees 94,300	Employees 81,0008% decrease	Employees 15,1068% increase
Valuation ($)	Valuation ($) 85.6 m	Valuation ($) N/A	Valuation ($) 2.7 b	Valuation ($) 163.9 b	Valuation ($) 102.2 b
Financial
Revenue (est.)	Revenue (est.) $42.2m (FY, 2025)	Revenue (est.) N/A	Revenue (est.) $58.7b (FY, 2025)	Revenue (est.) $62.6b (FY, 2025)	Revenue (est.) $14.3b (FY, 2025)
Cost of goods	Cost of goods $13.8m (FY, 2025)	Cost of goods N/A	Cost of goods $4.9b (FY, 2025)	Cost of goods $16.1b (FY, 2025)	Cost of goods N/A
Gross profit	Gross profit $28.4m (FY, 2025)	Gross profit N/A	Gross profit $54.2b (FY, 2025)	Gross profit $46.5b (FY, 2025)	Gross profit N/A
Net income	Net income $168m (FY, 2025)	Net income N/A	Net income $10.2b (FY, 2025)	Net income $7.8b (FY, 2025)	Net income $4.5b (FY, 2025)
Operating ⚠
Countries	Countries N/A	Countries N/A	Countries 130 (FY, 2021)	Countries 200 (FY, 2024)	Countries N/A
Phase I Trials Products	Phase I Trials Products N/A	Phase I Trials Products 28 (Jul, 2025)	Phase I Trials Products N/A	Phase I Trials Products 51 (FY, 2024)	Phase I Trials Products N/A
Phase II Trials Products	Phase II Trials Products 1 (FY, 2020)	Phase II Trials Products 19 (Jul, 2025)	Phase II Trials Products N/A	Phase II Trials Products 27 (FY, 2024)	Phase II Trials Products N/A
Phase III Trials Products	Phase III Trials Products 1 (FY, 2020)	Phase III Trials Products 41 (Jul, 2025)	Phase III Trials Products N/A	Phase III Trials Products 32 (FY, 2024)	Phase III Trials Products N/A
Projects in R&D Pipeline	Projects in R&D Pipeline 6 (FY, 2020)	Projects in R&D Pipeline N/A	Projects in R&D Pipeline 177 (FY, 2021)	Projects in R&D Pipeline N/A	Projects in R&D Pipeline N/A
Funding
Total funding raised	Total funding raised $ 174.5m	Total funding raised N/A	Total funding raised $ 1b	Total funding raised N/A	Total funding raised $ 53.9m